Last reviewed · How we verify
ST-100 (vezocolmitide)
ST-100 (vezocolmitide) is a small molecule that modulates the Wnt/β-catenin signaling pathway.
ST-100 (vezocolmitide) is a small molecule that modulates the Wnt/β-catenin signaling pathway. Used for Metastatic colorectal cancer.
At a glance
| Generic name | ST-100 (vezocolmitide) |
|---|---|
| Sponsor | ORA, Inc. |
| Drug class | Wnt pathway inhibitor |
| Target | Porcupine |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting the Wnt/β-catenin pathway, ST-100 (vezocolmitide) aims to reduce the proliferation of certain cancer cells. This mechanism is being explored for its potential to treat various types of cancer. Further research is needed to fully understand the effects of ST-100 (vezocolmitide) on this pathway.
Approved indications
- Metastatic colorectal cancer
Common side effects
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ST-100 (vezocolmitide) CI brief — competitive landscape report
- ST-100 (vezocolmitide) updates RSS · CI watch RSS
- ORA, Inc. portfolio CI